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Elizabeth Robertson, MBBS; Brett Hambly, PhD; Richmond Jeremy, MBBS, PhD
Background-—Marfan syndrome (MFS) and familial non–syndromal thoracic aortic aneurysm and dissection (ns-TAAD) are genetic
aortopathies causing aortic dilatation with increased aortic stiffness. Left ventricular (LV) contractility and ventricular-vascular
coupling index (VVI) were compared between MFS and ns-TAAD and determinants of VVI were investigated.
Methods and Results-—Patients with MFS (M 57, F 47) and ns-TAAD (M 72, F 39) were studied by echocardiography and
compared with controls (M 77, F 71). Aortic geometry, hemodynamics, LV work, LV contractility (end-systolic elastance [Ees]), and
VVI were documented. Aortic sinuses were equally dilated in MFS (19.72.4) and ns-TAAD (19.81.8) compared to controls
(16.21.4 mmm2, P<0.001). Aortic stiffness index was increased in MFS (9.75.1) and ns-TAAD (10.84.7) versus controls
(5.42.0, P<0.01); LV stroke work was unchanged in MFS (43674) compared to controls (43560) but increased in ns-TAAD
(492109 mJm2 P<0.01). The LV Ees was reduced in MFS (1.320.19) compared to controls (1.650.29 mm HgmL1,
P<0.01) but increased in ns-TAAD (1.830.30, P<0.01) and VVI was abnormal in MFS (0.710.11) compared to controls
(0.620.07, P<0.01) and ns-TAAD (0.620.09). Treatment with b-blockers was associated with partial normalization of VVI in
MFS. A VVI ≥0.8 was associated with increased risk of death and heart failure in MFS.
Conclusions-—Left ventricular contractility and ventricular-vascular coupling are abnormal in MFS but preserved in ns-TAAD, and
are independent of aortic stiffness, consistent with intrinsic impairment of myocardial contractility in MFS. ( J Am Heart Assoc.
2016;5:e003705 doi: 10.1161/JAHA.116.003705)
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T he arterial vasculature in young adults exhibits highcompliance, with low stiffness and pulse pressure, and
optimal coupling to left ventricular (LV) ejection. With increas-
ing age, elastin fragmentation and increased collagen in the
aorta result in increased vascular stiffness, contributing to
increased systolic blood pressure and LV afterload,1–3 which is
particularly evident after age 40 years.4 A feature of Marfan
syndrome (MFS) is accelerated elastin fragmentation, with
increased aortic stiffness beyond usual age-related changes.5,6
Other aortopathies, including non–syndromal familial thoracic
aneurysm and dissection (ns-TAAD) and aneurysm-osteoarthri-
tis syndrome, are associatedwith abnormal aortic stiffness.7 LV
systolic function and vascular load are closely coupled. This
relationship can be characterized as the interaction of time-
variant elastances of the ventricle and arterial vasculature,
described by the end-systolic pressure-volume relation and the
effective arterial elastance, respectively.8 Chronic changes in
vascular loading are associated with altered ventricular geom-
etry and function.9
A recent laboratory study, examining end-systolic pres-
sure-volume relations, has described abnormal myocardial
contractility in a mouse model of severe MFS, associated
with evidence of altered cardiomyocyte cell-signaling.10
Some clinical studies have described abnormal LV function
in MFS;11–14 however, others ﬁnd no abnormality15,16 and
data interpretation is confounded by inclusion of patients
receiving b-blockers and use of load-dependent measures
of ventricular function. Ventricular function in ns-TAAD has
not been systematically examined. b-Blockers and angio-
tensin-receptor blockers are used to ameliorate aortic
dilatation in MFS17 and by extrapolation in ns-TAAD;
however, as yet there is no conclusive data about the
effect of these medications on ventricular function in these
genetic aortopathies.
This study investigated ventricular-vascular coupling in
MFS and ns-TAAD. The primary aim was to compare the
degree of any LV functional impairment in MFS and ns-TAAD
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and to document the factors associated with LV function in
these aortopathies. The secondary aim was to examine the
potential protective effect or otherwise of b-blockers and
angiotensin-receptor blockers on ventricular function.
Methods
Study Groups
Participants in this study were enrolled in the Marfan and
Aortic Disease Clinic at Royal Prince Alfred Hospital, Sydney.
A full medical history, physical examination, and echocardio-
graphic imaging were obtained at enrollment. Individuals were
considered to have aortic disease if they manifested thoracic
aortic aneurysm or dilatation (Z score >2 adjusted for age and
body size).18
This consecutive study group includes all eligible individ-
uals aged ≥16 years, attending the clinic between January
2010 and June 2015. Controls include patients referred for
assessment, who had normal hearts without aortic dilatation.
Diagnosis of MFS was according to revised Ghent criteria.19
Diagnosis of ns-TAAD required aortic dilatation in absence of
known risk factors plus family history of aortic aneurysm/
dissection in a ﬁrst-degree relative or known pathogenic gene
variant. Individuals with hypertension, atherosclerosis, aorti-
tis, or bicuspid aortic valve disease were ineligible. Patients
with mitral/aortic regurgitation of more than mild degree or
atrial ﬁbrillation were excluded, as were patients with
coronary artery disease (history or symptoms of ischemia,
abnormal ECG, or documented coronary disease), previous
cardiac/aortic surgery, or aortic dissection.
Echocardiography
Complete 2-dimensional echocardiography, including Doppler
ﬂow interrogation, was performed according to standard
techniques. Images were analyzed in duplicate by 2 indepen-
dent observers and the mean of their observations was used
for data analysis. Brachial sphygmomanometry was per-
formed at the end of the echocardiography examination and
central aortic pressure calculated according to published
data.20 The end-systolic aortic pressure (Pes) was estimated
as 0.99peak systolic pressure (Psys) and aortic stiffness (SAo)
was calculated from end-diastolic and end-systolic aortic
diameters at the sinuses of Valsalva, as previously described.6
Left ventricular geometry was measured with calculation of
biplane end-diastolic/end-systolic volumes (biplane method
of disks) and LV mass (2-dimensional truncated ellipsoid
model) according to published standards.21 The LV ejection
velocities were measured by pulse-wave Doppler at below the
aortic valve, with calculation of stroke volume22,23 from the
Doppler velocity-time integral. Left ventricular stroke work
(LVSW) was calculated as the product of LV stroke volume
and mean arterial pressure less estimated LV end-diastolic
pressure (15 mm Hg).24 Left ventricular systolic time inter-
vals were measured from the aortic Doppler signal, including
isovolumic contraction time (TIVC), ejection time (TEJECT), and
total systolic time (TSYS) and LV myocardial velocities in
systole and diastole were measured at the basal interventric-
ular septum by tissue Doppler.23 The LV dP/dt was calculated
as the quotient of LV developed pressure at aortic valve
opening and isovolumic contraction time.
The LV end-systolic pressure volume relation was calcu-
lated according to the single-beat technique of Chen et al.25
Indices of LV work, systemic vascular resistance (SVR), aortic
elastance (Ea), end-systolic LV elastance (Ees), and the
ventricular-vascular coupling ratio (VVI) were calculated
according to published methods.8 The mean interobserver
variations in determination of Ees, Ea, VVI, and LVSW were
17.7%, 12.7%, 13.3%, and 12.7%, respectively.
Data Analysis
Discrete data are described as proportions/frequency. Nor-
mality of continuous data distributions was tested by Kol-
mogorov–Smirnov and Shapiro–Wilk tests. As data sets were
often not normally distributed, a bisquare-weighted ANOVAwas
performed according to the method of Regeth and Stine,26 with
r=3 SDs for removal of outliers and iterations were continued
until incremental change in weighted mean was <1%. Contin-
uous data are reported as weighted meanSD and also as
median and interquartile range. When ANOVA detected signif-
icant differences within data sets, intergroup comparisons were
performed by post-hoc tests: Tukey test if equal group variances
or Dunnetts T3 test if group variances were unequal by Levene
test. Discrete data were compared by v2 test. Correction by
Bonferroni method was made for multiple comparisons as
required. Relationships between continuous variables were
compared by least-squares regression, with stratiﬁcation by
aortopathy type and age. Primary comparisons were between
controls, MFS, and ns-TAAD groups. Secondary comparisons
were between age, sex, and treatment subgroups in the Marfan
and ns-TAAD groups. For comparisons of Ea, Ees, VVI, and LVSW
per 100 g myocardium, in the current data set, a minimum
group size of 50 allows detection of a difference in means of
≥15%, and a minimum group size of 25 allows detection of a
difference in means of ≥25%, with power >80% at a=0.05. Data
analysis was performed using the SPSS v.24 package (IBM Inc
2016) and a P<0.05 is described as signiﬁcant.
Ethics and Privacy
Patients gave consent for echocardiography and clinical data
collection at the time of examination and clinical records data
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use is approved by the hospital Human Research Ethics
Committee (Protocols X12-0304 and X15-0382). Each author
has contributed to this study, including design and data
analysis, and to preparation of the manuscript. All authors
have read and approved the manuscript as submitted.
Results
Study Groups
Among 944 patients attending the Clinic during the enroll-
ment period, 187 had MFS (83 excluded with dissection,
surgery, and valve regurgitation); 223 had ns-TAAD (112
excluded with dissection, surgery, and valve regurgitation);
148 had no aortic disease; 254 had bicuspid valve aneurysm;
82 had hypertensive/atherosclerotic disease; and 50 had
other conditions (Loeys–Dietz syndrome, Ehlers–Danlos syn-
drome, and aortitis). A total of 363 individuals were included
(148 controls, 104 MFS, 111 ns-TAAD). Among MFS patients,
63 were not taking any medication and 41 were taking
medication: 29 b-blockers; 12 angiotensin II receptor block-
ers. Among the ns-TAAD patients, 67 were taking no
medication and 44 were taking medication (16 b-blockers,
28 angiotensin II receptor blockers).
Demographics of the groups are compared in Table 1.
There were more males in the ns-TAAD group and patients
with ns-TAAD group were slightly older than controls or MFS
patients. A family history of aortic disease was present in
nearly all MFS and ns-TAAD patients; however, pathogenic
gene mutations remain unknown for most ns-TAAD patients.
Systolic (Psys), diastolic (Pdias), and mean (Pmean) aortic
pressures were comparable between MFS and controls but
signiﬁcantly greater in ns-TAAD patients, as was the pulse
pressure (Ppulse). Both Psys and Pmean increased with age in all
groups (Figure 1); however, the increase was more marked in
the ns-TAAD group than in the control or MFS groups. Greater
Psys and Pmean were observed in both males and females with
ns-TAAD (Figure 2).
Aortic Geometry and Hemodynamics
Dilatation of the sinuses of Valsalva was comparable in MFS
and ns-TAAD groups; however, dilatation of the ascending
aorta was more severe in ns-TAAD (Table 1). Aortic diameter
at both sinuses of Valsalva and ascending aorta increased
with age in controls (Figure 3). In MFS, the rate of increase in
aortic diameter with age appeared greater than in controls,
although there was considerable variation between individu-
als. Similar ﬁndings were observed in the ns-TAAD group.
Aortic diameters at both sinus of Valsalva and ascending
aorta were comparable for both males and females with MFS
and ns-TAAD (Figure 2).
Aortic stiffness was signiﬁcantly greater in both MFS and
ns-TAAD groups than in controls (Table 1), but did not differ
between males and females with either MFS or ns-TAAD
(Figure 2). Aortic stiffness increased with age in controls
(Figure 4) and also in MFS and ns-TAAD groups, although
there was wide variability in the degree of aortic stiffness in
both of these aortopathy groups. The systemic vascular
resistance index (SVRI) was greater in ns-TAAD than in
controls (Table 2 and Figure 4).
LV Geometry and Systolic Function
Among patients taking no medication, the LV end-diastolic
volume index did not differ between groups, but LV end-
diastolic volume index was slightly greater in MFS patients
taking b-blockers (Table 2), as was the LV stroke volume
index. The LV end-systolic volume index and LV ejection
fraction were not signiﬁcantly different between groups
(Table 2). The cardiac index was lower in both MFS and ns-
TAAD groups, consistent with the lower resting heart rate in
these patients.
LV mass index was signiﬁcantly greater in both MFS and
ns-TAAD compared to controls, with a concentric pattern of
wall thickening (Table 2). The greatest increase in LV mass
was observed in the ns-TAAD group. The LV mass index was
greater in males in all groups (Figure 5). The LV mass index
increased with age in controls (Figure 6); however, no
signiﬁcant age dependency was evident in either MFS or ns-
TAAD groups.
Heart rate was lower in both MFS and ns-TAAD groups
than in controls (Table 1). The TIVC and TEJECT were prolonged
in MFS but not in ns-TAAD (Table 2). The greatest increase in
TEJECT was observed in MFS patients taking b-blockers.
Tissue Doppler indices differed between groups; peak
systolic contraction velocity S0 and peak early diastolic
relaxation velocity E0 were reduced in MFS and ns-TAAD
(Table 2). The A0 velocity was increased in ns-TAAD but mildly
reduced in MFS. The peak S0 did not differ with age in any
group. Diastolic ﬁlling velocities did change with age; the A0
velocities increased with age and the E0 decreased with age in
each group. Neither systolic nor diastolic tissue velocities
differed between males and females in any group.
The LV stroke work index (LVSWI) was similar between
controls and MFS but was increased in ns-TAAD, as was LV
minute work (Table 3). Similarly, LV power was increased in
ns-TAAD but not MFS compared to controls. There was no
difference in LVSWI between males and females in control or
MFS groups, although lower LVSWI was observed in males
with ns-TAAD than in females (Figure 5). The LVSWI increased
with age in all groups and there was no difference between
controls and MFS; however, the relationship differed for ns-
TAAD (Figure 7). The LV minute work per 100 g myocardial
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mass was reduced for both MFS and ns-TAAD compared to
controls (Table 3), particularly in males (Figure 5). There was
no relationship between age and LV work per unit mass in any
group (Figure 6).
Ventricular-Vascular Coupling
Left ventricular dP/dt was reduced in MFS but similar to
controls in ns-TAAD (Table 3). The LV end-systolic elastance
(Ees) was reduced in MFS but was increased compared to
controls in ns-TAAD. There was no difference in LV Ees
between males and females in any group (Figure 5). In the
control group, LV Ees increased with age (Figure 8) and a
similar relationship was observed for ns-TAAD. There was only
a weak relationship between LV Ees and age in MFS, which
differed from controls.
The arterial elastance (Ea) was greater in ns-TAAD
compared to controls, but was comparable to controls in
MFS patients not receiving medication (Table 3). Arterial
elastance increased with age in controls and ns-TAAD, but not
in MFS (Figure 7). The ventricular vascular coupling ratio (VVI)
was increased in MFS but similar to controls in ns-TAAD.
There was no difference in Ea or VVI between males and
females in any group (Figure 5). The VVI did not change with
age in any group (Figure 8).
Effect of b-Blockers on Ventricular-Vascular
Coupling in MFS and ns-TAAD
Patients taking b-blockers in the MFS and ns-TAAD groups
were of similar age and demographics to those without
b-blockers (Table 1). Among MFS patients taking b-blockers,
heart rate was lower than in MFS without b-blockers. Among
ns-TAAD patients taking b-blockers, neither heart rate nor Pes
differed signiﬁcantly from ns-TAAD patients without
b-blockers. There was no discernible effect of b-blockers on
aortic stiffness.
The LV end-diastolic volume index, LV stroke volume index,
and LV ejection fraction were greater in MFS patients taking
b-blockers than in those without (Table 2), although cardiac
A
B
Figure 1. Relationships between age and systolic central aortic pressure (A) and mean central aortic pressure (B) for control (green), MFS
(blue), and ns-TAAD (red) groups. ns-TAAD indicates nonsyndromal thoracic aortic aneurysm and dissection. MFS indicates Marfan syndrome;
ns-TAAD, ns-TAAD, non–syndromal thoracic aortic aneurysm and dissection.
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index and SVRI did not differ. Among ns-TAAD patients taking
b-blockers, the LV end-diastolic volume index and LV stroke
volume index and LV ejection fraction did not differ from those
without b-blockers, although cardiac index was slightly less.
The LV mass index did not differ between those taking
b-blockers and those without in either the MFS or ns-TAAD
groups.b-Blockers did not further prolong TIVC inMFS; however,
both TEJECT and TSYS were prolonged by b-blockers in MFS.
The tissue Doppler indices were similar for those taking




Figure 2. Aortic geometry and hemodynamics according to sex and aortopathy. Data are shown for all
patients, irrespective of treatment. Diameters of sinuses of Valsalva (A) and ascending aorta (B); stiffness of
aortic sinuses (C); peak systolic pressure (D); mean aortic pressure (E); and systemic vascular resistance
index (F) for control (green), Marfan (blue) and ns-TAAD (red) groups, according to sex. *P<0.05, **P<0.01
vs controls in same sex group. Number of patients in groups shown in (A). ns-TAAD indicates non–
syndromal thoracic aortic aneurysm and dissection.
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groups (Table 2). Among the MFS patients, the LVSWI and LV
minute work did not differ between those taking b-blockers
and those without (Table 3) and the LV work per gram LV
mass was also similar for those with and without b-blockers.
Among the ns-TAAD patients, those taking b-blockers had
lower LVSWI, LV minute work, and LV work per 100 g LV
mass than did those without b-blockers.
The LV dP/dt and Ees did not differ between those taking
b-blockers and those without b-blockers for either the MFS or
ns-TAAD groups. Among MFS patients, those taking b-blockers
had lower Ea and lower VVI than did those without b-blockers.
In contrast, among the ns-TAAD group, Ea and VVI did not differ
between those taking b-blockers and those without.
Effect of Angiotensin II Receptor Antagonists on
Ventricular-Vascular Coupling in MFS and ns-
TAAD
Among the MFS patients, those taking angiotensin II (AgII)
antagonists were slightly older than those without; otherwise,
demographics of those taking AgII antagonists in the MFS and
ns-TAAD groups were similar to those not taking AgII
antagonists (Table 1). Heart rate and blood pressure did not
signiﬁcantly differ from controls or from those without AgII
antagonists in either the MFS or ns-TAAD groups. Aortic
geometry was similar for those with and without AgII
antagonists in both MFS and ns-TAAD groups.
LV volumes, cardiac index, and SVRI were similar for those
taking AgII antagonists and those without in the MFS and ns-
TAAD groups, as were systolic time intervals and tissue Doppler
indices (Table 2). In both MFS and ns-TAAD groups, LV work
was similar for those with and without AgII antagonists
(Table 3). Indices of LV contractility, including dP/dt and Ees,
were unchanged by AgII antagonists in either the MFS or ns-
TAAD groups (Table 3). Similarly, both Ea and VVI were
unchanged by AgII antagonists in theMFS and ns-TAAD groups.
Determinants of Ventricular-Vascular Coupling
Index
Univariate predictors of the VVI are summarized in Table 4.
The most signiﬁcant predictors included aortopathy group, LV
A
B
Figure 3. Relationships between age and maximum diameter of sinuses of Valsalva (A) and ascending aorta (B) for control (green), MFS (blue),
and ns-TAAD (red) groups. MFS indicates Marfan syndrome; ns-TAAD, non–syndromal thoracic aortic aneurysm and dissection.
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end-systolic volume index, LV dP/dt, LVSWI, and tissue
Doppler S0 velocity. There was no relationship between age,
sex, or aortic stiffness and VVI.
A multivariate model, which describes approximately two
thirds of the variance in VVI, is summarized in Table 4. The LV
volumes, contractility (LV dP/dt), and SVRI were signiﬁcant
independent predictors, as was the aortopathy group and use
of b-blockers.
Clinical Correlation of Ventricular-Vascular
Coupling
The distributions of VVI are compared for controls, MFS, and
ns-TAAD in Figure 9. The controls and the ns-TAAD patients
exhibit essentially normal distributions with limited skewness
towards higher VVI values in a small number of patients. In
contrast, MFS appears to be associated with a bimodal
distribution, with a second peak in VVI values ≥0.80.
There were 32 (31%) MFS patients with VVI ≥0.8, of whom
12 were female compared to 35 of the 72 with VVI <0.80
(NS). There was no difference in age between those with VVI
≥0.80 (3215 years) and those with VVI <0.80 (3214).
Those with VVI ≥0.80 had lower peak S0 than those with VVI
<0.80 (6.92.1 versus 8.11.6 cms1, P=0.01) and also
lower LVSWI (39887 versus 471117 mJm2, P=0.006).
There was familial clustering of MFS patients with VVI
≥0.80 with 4 pedigrees including 12 of the patients. Among
the patients with VVI ≥0.80, 22 had known FBN1 mutations,
of which 13 were missense, 3 were premature stop codons,
and 6 were insertion/deletions or splice site variants.
Among the MFS patients with VVI <0.80, 39 had known
FBN1 mutations of which 21 were missense, 9 were stop
codons, and 9 were insertion/deletions or splice site
variants.
Among the MFS patients with VVI ≥0.80, 1 died suddenly
and 1 died of heart failure during the study period. Another
developed clinical heart failure during the study period. Three
other MFS patients with VVI ≥0.80 had ﬁrst degree-relatives
who died with heart failure. None of the MFS patients with VVI
<0.80 developed heart failure and none died during the study
period. None of the ns-TAAD patients had heart failure and
none died during the study period.
A
B
Figure 4. Relationships between age and aortic stiffness index (A) and systemic vascular resistance index (B) for control (green), MFS (blue),
and ns-TAAD (red) groups. MFS indicates Marfan syndrome; ns-TAAD, non–syndromal thoracic aortic aneurysm and dissection.
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This study compared LV systolic function and ventricular-
vascular coupling in patients with MFS and ns-TAAD aor-
topathies and describes impaired coupling in MFS but not in
ns-TAAD. The degree of abnormal ventricular-vascular cou-
pling in MFS is independent of aortic stiffness, appears to
have a signiﬁcant genetic foundation, and is partly reversed by
b-blockers.
Ventricular-Vascular Coupling in Genetic
Aortopathy
Previous studies of LV function in MFS have been discordant
with some reporting impaired contractility,11–13 and others
observing no difference in ventricular function between
controls and MFS.15,16 Several factors may be responsible
for this discrepancy, including patient selection, use of load-




Figure 5. Left ventricular work and ventricular-vascular coupling according to sex and
aortopathy. Data shown for all patients, irrespective of treatment. Left ventricular stroke
work index (A), ventricular mass (B), and work per gram of ventricular mass (C), with end-
systolic elastance (D), arterial elastance (E), and ventricular-vascular coupling index (F) for
control (green), Marfan (blue), and ns-TAAD (red) groups, according to sex. *P<0.05,
**P<0.01 vs controls in same sex group. Number of patients in groups is shown in (A). LV
indicates left ventricular; ns-TAAD, non–syndromal thoracic aortic aneurysm and
dissection.
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patients taking b-adrenergic blockers. Our understanding has
been further clouded by uncertainty about the relative
contributions of altered afterload, consequent upon increased
aortic stiffness, and intrinsic impairment of myocardial
contractility to ventricular-vascular coupling in MFS. Studies
using tissue Doppler measurements of myocardial function
have been reported for MFS;27,28 however, these indices can
also be affected by ventricular afterload.29 This study
therefore documented the LV end-systolic pressure-volume
relation, and ventricular-vascular index, in order to better
account for issues of ventricular loading.30
Increased aortic stiffness and systemic vascular resistance
are features of aging, and are associated with increased
systolic blood pressure and pulse pressure. In both MFS and
ns-TAAD, aortic stiffness is increased beyond controls of
similar age; however, the blood pressure responses differ. In
the ns-TAAD group, both PSys and PPulse are signiﬁcantly
greater than controls; however, this was not observed in MFS.
Although the ns-TAAD group was a decade older than the
control and MFS groups, the difference in blood pressure and
SVRI was still observed after age was taken into account.
These ﬁndings suggest an intrinsic change in systemic
vasoregulation in ns-TAAD, which will require future investi-
gation.
The present data show that ventricular-vascular coupling
may be altered in MFS but is preserved in ns-TAAD. The
most likely underlying cause is an intrinsic impairment of
myocardial contractility in MFS, and the current observations
of reduced LV dP/dt, tissue S0, and Ees are consistent with
such. There was no signiﬁcant relationship between aortic
stiffness and Ees. These observations are concordant with a
report of abnormal end-systolic pressure-volume relations in
mice with MFS.10 As ﬁbrillin1 is an important component of
the extracellular microﬁbrils, the most likely mechanism of
such impairment is altered myocardial force development,
consequent upon abnormal coupling of myocytes to the
extracellular connective tissue, via integrins and the
microﬁbrils.31 The present observations of prolonged TIVC




Figure 6. Relationships between age and left ventricular mass index (A) and left ventricular work per unit LV mass (B) for control (green), MFS
(blue), and ns-TAAD (red) groups. LV indicates left ventricular; MFS, Marfan syndrome; ns-TAAD, non–syndromal thoracic aortic aneurysm and
dissection.
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The observed impairment of ventricular contractility and
abnormal VVI in MFS is a relatively subtle ﬁnding and appears
to affect only approximately one third of patients. A similar
observation was reported from data collected by the GenTAC
registry.10 This intragroup variability may explain some of the
previously discrepant ﬁndings about ventricular function in
MFS.
Increased LV mass was observed in the MFS group in the
absence of increased blood pressure, and this ﬁnding is
consistent with ﬁndings in MFS mice,10 in which LV hyper-
trophy is observed, as an apparent compensatory response to
impaired contractility. The resting LV work per unit mass of
myocardium was reduced in the MFS group, indicating that
hypertrophy alone does not appear to fully compensate for
impaired contractility. Increased LV mass was also observed
in the ns-TAAD group, consistent with the increased blood
pressure and LV work in this group. Interestingly, the resting
LV work per unit mass of myocardium was also less than
controls in the ns-TAAD group, most likely reﬂecting exercise-
related hemodynamics and stimulus to myocardial growth.
Determinants of Ventricular-Vascular Coupling
Index
The ventricular-vascular coupling index is described as the
ratio Ea/Ees and in this study, the changes in VVI resulted
from changes in Ees rather than changes in Ea except for
MFS patients taking b-blockers. The Ea is a lumped variable
describing ventricular afterload and is inﬂuenced by sys-
temic vascular resistance and blood pressure.30 The Ea is
not a measure of aortic stiffness and there was no
correlation with aortic stiffness in the present study groups.
The Ees is often described as a measure of intrinsic
myocardial contractility; however, this is subject to several
caveats, including some afterload inﬂuence and a nonlinear
end-systolic pressure-voluem relation. Notwithstanding this,
the ratio Ea/Ees is a useful descriptor of ventricular-vascular
coupling, provided its limitations are recognized. In clinical
studies, mean Ea/Ees ratios are reported as 0.6 to 0.8;
however, LV stroke work and efﬁciency remain at >90%




Figure 7. Relationships between age and left ventricular stroke work index (A) and arterial elastance (Ea) (B) for control (green), MFS (blue),
and ns-TAAD (red) groups. LV indicates left ventricular; MFS, Marfan syndrome; ns-TAAD, non–syndromal thoracic aortic aneurysm and
dissection.
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We found no greater deterioration in LV function or VVI with
age, consistent with an earlier report.33 Differences in LV
contractility have been reported for men and women,34
particularly in older individuals,35 but no such differences were
observed in the present study groups, although smaller
numbers among older MFS patients may have obscured some
differences. Although ns-TAAD appears to be more prevalent in
males than females, there were no differences in aortic
geometry or hemodynamics between sexes in MFS or ns-TAAD.
The principal independent predictors of VVI in multivariate
analysis were LV systolic volume indices, LV contractility (as
indexed by LV dP/dt), and systemic vascular resistance.
Aortopathy group was also a signiﬁcant independent predictor
of VVI. Finally, treatment with b-blockers was also a predictor
of VVI.
Protective Effects of Medication in MFS
There is a body of evidence supporting a beneﬁt of b-blockers
in reducing the rate of aortic dilatation in MFS. Within the
constraints of a nonrandomized study, the present data
suggest additional potential beneﬁt of b-blockers, with some
normalization of VVI in MFS receiving b-blockers. Treatment
with b-blockers did not affect Ees in either the MFS or ns-
TAAD groups.
The lower VVI in the MFS b-blocker group reﬂects a lower
Ea, which is consequent upon a greater LV stroke volume with
lower heart rate. The protective effect of b-blockers in
patients with heart failure is well established and the present
ﬁndings suggest that b-blockers may have additional beneﬁt
for patients with MFS. This hypothesis should be further
explored in a randomized study.
The use of renin–angiotensin–aldosterone system in-
hibitors may also be of beneﬁt for protection of the aorta in
MFS and is also well established for treatment of heart failure.
There was no beneﬁt of renin–angiotensin–aldosterone sys-
tem inhibitors upon VVI observed in MFS patients; however,
the numbers of patients in the present study are small and the
beneﬁt of these drugs upon LV function in MFS should be
examined in a randomized study.
A
B
Figure 8. Relationships between age and left ventricular end-systolic elastance (Ees) (A) and ventricular-vascular coupling index (B) for control
(green), MFS (blue), and ns-TAAD (red) groups. LV indicates left ventricular; MFS, Marfan syndrome; ns-TAAD, non–syndromal thoracic aortic
aneurysm and dissection.
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The present ﬁndings indicate that those MFS patients with a
higher VVI (≥0.80) appear to be identiﬁable as a high-risk
group. These individuals had a greater incidence of clinical
heart failure and death during the study period than did those
with lower VVI. Interestingly, there appears to be familial
clustering of individuals with abnormal VVI. A correlation
between non-missense FBN1 mutations and impaired LV
function has been described,36,37 although such a pattern was
not evident in the present MFS group. Thus, the VVI may be
useful as a novel risk stratiﬁer for individuals with MFS. This
would be consistent with data from the heart failure
population, in whom an abnormal VVI is indeed associated
with a more adverse prognosis.38 Our ﬁndings support the
conclusion of laboratory studies that the LV in MFS may have
impaired tolerance to increased hemodynamic load. Thus,
clinicians should consider earlier intervention for valve lesions
such as mitral regurgitation for individuals with MFS.
Individuals with MFS and a family history of heart failure
should have close follow-up of LV function as well as aortic
geometry and valve function.
The calculation of Ees and VVI are not part of standard
clinical echocardiography; however, the actual direct mea-
surements required for the calculation of these parameters
are straightforward and in routine use, such as stroke volume.
Additional measurements of systolic timing intervals are
easily obtained from ECG and Doppler recordings. With the
availability of these basic measurements, calculation of Ees
Table 4. Predictors of Ventricular-Vascular Coupling Index
Univariate
Variable Standardized ß t statistic Signiﬁcance R2
Group 0.362 6.442 <0.0001 0.131
LVEDVI 0.114 1.909 0.057 0.013
LVESVI 0.375 6.710 <0.0001 0.140
LV dP/dt 0.705 16.534 <0.0001 0.496
Pes 0.057 0.956 0.340 0.003
LVSWI 0.287 4.969 <0.0001 0.082
SVRI 0.207 3.519 0.001 0.039
Age 0.060 1.006 0.315 0.004
Sex 0.054 0.900 0.369 0.003
Ao stiffness 0.029 0.471 0.638 0.001
S0 velocity 0.318 5.136 <0.0001 0.097
Multivariate
Variable Standardized ß t statistic Signiﬁcance
(Constant) 20.714 <0.0001
LVESVI 0.317 9.713 <0.0001
LVSWI 0.150 4.333 <0.0001
Group 0.166 4.650 <0.0001
LV dP/dt 0.532 14.647 <0.0001
SVRI 0.199 6.166 <0.0001
b-blocker 0.111 3.269 0.001
Model for all patients in study. Model R2=0.641; SEE=0.082; P<0.0001. Ao indicates
aorta; LV dP/dt, rate of change in left ventricular pressure in early systole; LVEDVI, left
ventricular end-diastolic volume index; LVESVI, left ventricular end-systolic volume index;
LVSWI, left ventricular stroke work index; Pes, end-systolic blood pressure; S0 , systolic






































Figure 9. Distribution of VVI between controls, MFS, and ns-
TAAD. Data are shown for patients in each group receiving no
medication. The proportion of MFS patients with VVI ≥0.8 was
31% compared to 7% of controls and 10% of ns-TAAD (P<0.001 for
both control and ns-TAAD vs MFS). MFS indicates Marfan
syndrome; ns-TAAD, non–syndromal thoracic aortic aneurysm
and dissection; VVI, ventricular-vascular index.
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and VVI can be easily undertaken with a spreadsheet with the
relevant formulae embedded. The use of more advanced
echocardiography techniques, including strain and 3-dimen-
sional volumetrics, is also likely to yield clinically useful
information and should be examined in future studies of
clinical outcomes.
Study Limitations
The present study was a consecutive series of patients
recruited over several years. Comparisons between patients
receiving b-blockers or renin–angiotensin–aldosterone sys-
tem antagonists and those without medication are not
randomized. Future study of b-blockers and ventricular
vascular coupling in MFS patients may be warranted,
including prognostic studies in higher risk MFS patients.
Our present observations were acquired with subjects under
resting conditions, and the question of how the LV responds
to exercise in MFS and ns-TAAD will also warrant investiga-
tion. Finally, our clinical data suggest that VVI may be a useful
prognostic marker for MFS; however, this should be investi-
gated in a future longitudinal study.
Conclusions
LV contractility and ventricular-vascular coupling are abnor-
mal in MFS, but are preserved in ns-TAAD. The impaired
function appears to be intrinsic to the MFS ventricle and is
independent of aortic stiffness. The ventricular-vascular index
may serve as an identiﬁer of MFS individuals at higher risk of
heart failure and sudden death, whereas b-blockers may
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